Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 12, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Factor XIII assays.

Stephen Opat1, Jenny Butler, Erica Malan

  • 1Department of Haematology, Monash Medical Centre, Clayton, VIC, Australia.

Methods in Molecular Biology (Clifton, N.J.)
|April 3, 2013
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

Internal medicine journal·2026
Same author

Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma.

HemaSphere·2026
Same author

Significant variations in first-line mantle cell lymphoma care-an Australasian Lymphoma and Related Diseases Registry study.

Leukemia & lymphoma·2026
Same author

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Blood advances·2026
Same author

Familial pseudohyperkalaemia: An unusual cause of artefactual hyperkalaemia.

Annals of clinical biochemistry·2026
Same author

Development and Validation of Prognostic Models for Treatment Response of Patients with B-Cell Lymphoma: Standard Statistical and Machine-Learning Approaches.

Journal of clinical medicine·2025
Same journal

Tracking Synthetic Adhesins on Bacterial Surfaces with Immunofluorescence Microscopy.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Post-Selection Methods for Analyzing mRNA Display Selections and Optimization of Hits.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

High-Performance Computing in Tandem Mass Spectrometry (MS/MS) Peptide Identification.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Engineering and Adapting Disulfide-Containing Proteins to Enable Intracellular Functionality.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

AI-Driven Protein Research: From Prediction to Design.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Methods for the In Vitro Selection of Protein and Peptide Libraries Using mRNA Display.

Methods in molecular biology (Clifton, N.J.)·2026
See all related articles

Factor XIII (FXIII) deficiency, a rare bleeding disorder, is manageable with plasma products. Assays are crucial for diagnosis and treatment, despite some limitations in sensitivity.

Area of Science:

  • Hematology
  • Coagulation Disorders
  • Diagnostic Assays

Background:

  • Factor XIII (FXIII) deficiency is a rare genetic disorder causing bleeding and pregnancy loss.
  • Effective treatment involves plasma products, necessitating accurate diagnostic tools.

Purpose of the Study:

  • To highlight the importance of reliable Factor XIII (FXIII) assays.
  • To discuss the diagnostic and therapeutic guidance provided by FXIII activity tests.

Main Methods:

  • Review of diagnostic tests for Factor XIII (FXIII) activity.
  • Analysis of assay performance, including sensitivity and potential for overestimation.

Main Results:

  • Existing diagnostic tests for FXIII activity, while not complex, have limitations.

More Related Videos

Extracellular Vesicle Tissue Factor Activity Assay
03:53

Extracellular Vesicle Tissue Factor Activity Assay

Published on: December 29, 2023

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Related Experiment Videos

Last Updated: May 12, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Extracellular Vesicle Tissue Factor Activity Assay
03:53

Extracellular Vesicle Tissue Factor Activity Assay

Published on: December 29, 2023

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

  • Assays may exhibit reduced sensitivity and overestimate activity at lower levels.

    • Conclusions:

    • Despite limitations, current FXIII activity assays are adequate for diagnosing and managing most patients with clinically significant deficiency.
    • Reliable FXIII testing is essential for guiding prophylaxis and replacement therapy.